The RND Group, Inc.

The RND Group, Inc. specializes in medical device software development, providing comprehensive solutions that integrate software and hardware specifically designed for the healthcare industry. Founded in 1997 in Indianapolis, US, The RND Group, Inc. is a medical device software development firm.

The company has maintained a consistent focus on providing innovative software solutions without significant pivots in its business strategy. Miraldo Sinaulan is recognized as the founder, and the current CEO is Neelesh Hanswani. The firm has completed a total of 1 deal, with the most recent occurring on December 7, 2021, when Gener8 LLC acquired The RND Group, Inc. Financial details of this deal were not disclosed.

The RND Group specializes in medical device software development, offering FDA-ready software solutions tailored for in vitro diagnostic products (IVDs) and Software as a Medical Device (SaMD) projects. Their service offerings include the FDA Readiness Assessment, Application Accelerator, LIS Connector, and the RND Group Device Portal, aimed at enhancing medical device functionality and compliance. These products cater primarily to healthcare companies in North America and Europe, facilitating efficient integration of medical devices with laboratory information systems (LIS) and electronic health records (EHR). The RND Group generates revenue through B2B relationships with healthcare companies requiring custom software and hardware solutions.

Their pricing structure primarily consists of project-based fees for software development, ongoing maintenance, and subscription models for cloud-based services, such as the Device Portal. Key offerings like the FDA Readiness Assessment and Application Accelerator are marketed as essential tools to streamline the regulatory approval process, with clients typically engaging in contracts that involve upfront payments and recurring fees, ensuring a stable revenue stream. The RND Group aims to enhance its product lineup and expand its market reach, particularly into new geographic regions. Following its acquisition by Gener8 LLC in December 2021, the company plans to leverage additional full lifecycle software development capabilities to extend its operations within life sciences software development.

While specific upcoming product launches are not detailed, the integration with Gener8 LLC is anticipated to support these initiatives and bolster their service offerings in the life sciences sector.